Neuroendocrine Cancer: At least 50 shades of grey


If you read any authoritative source on this cancer, it will normally begin with “Neuroendocrine Neoplasms (NENs) are heterogeneous tumours ………….”.  The term heterogeneous means diverse in character or content; or a structure with dissimilar components or elements.  This is not surprising as these tumours are found in Neuroendocrine cells throughout the vast majority of the human anatomy. 

And yet, when you look at many hospital/healthcare sites, advocate organisation sites, and cancer information sources not maintained by Neuroendocrine Cancer scientists or specialists, you might start to think there is just one big type of NET and only one syndrome. Once again, this is partly related to the lingering use of the term Carcinoid. Even within the community, so many people make blanket statements about Neuroendocrine Cancer which are misleading, e.g.

“they’re all slow growing”,
“they all have carcinoid syndrome”,
“they’re all at risk of (so-called) carcinoid crisis”,
“they all oversecrete serotonin”, 
“they all have hormones thrashing around their bodies”,
“chemo doesn’t work for NETs”,
“they’re all incurable”,
“they’re all rare”,
……. I could go on. 

In my opinion, all untrue and/or misguided, and many of these myths are connected to the incorrect use of the term Carcinoid to describe all types of this cancer; and not helped by a lack of robust moderation in groups. 

It’s about Grading and Differentiation

In truth, and at the highest level, the most up-to-date classification system allows for two fundamentally different groups of NENs: well-differentiated, low-proliferating NENs, called neuroendocrine tumours (NETs), and poorly differentiated, highly proliferating NENs, called small- or large-cell neuroendocrine carcinomas (NECs).

Even within a single grade, there can be huge differences, e.g. in Grade 3, the differentiation becomes crucial and may heavily influence therapy and prognosis. 

I must also mention the possibility of further shades of grey by introducing Mixed neuroendocrine-non-neuroendocrine neoplasms (MiNEN)read more here

It’s about the primary location(s)

Another striking difference is in the primary locations.  Well-differentiated NENs are more common in the pituitary, thyroid, parathyroid, thymus, stomach, small bowel, appendix, rectum, and pancreas, while poorly differentiated NENs are relatively more common in the lung, esophagus, colon, urogenital organs, and skin.  So many different shades of grey.

It’s about Staging

Within that, the epidemiological significance of the stage of each tumour can produce many shades, e.g. statistics over decades show that some tumour types will rarely or infrequently metastasise beyond the local area, while other types are prone to metastases, with many presenting at Stage 4.

In the group of the Gastroenteropancreatic NENs (GEP NENs), there are subtle differences between small intestine (particularly ileal), appendiceal, and pancreatic NETs. Ileal and appendiceal NETs, though sharing the production of serotonin, differ fundamentally in their clinical course, which is largely indolent (tumours often behaving in a benign fashion) in appendiceal NETs but usually malignant in ileal NETs. In contrast, ileal NETs follow a more indolent course than Pancreatic NETs, also differing profoundly in their molecular profile. 

Small localised low-grade appendiceal, type 1 gastric NET, and rectal NETs are typically indolent and rarely metastasise.  Small, localised tumours are normally excised with curative intent (NET specialist words not mine) and may never bother the person again.  Others may need longer surveillance periods.

At stage 4, cancer is said to be incurable but with low-grade well-differentiated NETs, stage 4 is not the red flag it is with other aggressive cancers and while it may be incurable, it is not untreatableIncurable is not necessarily terminal in indolent low-grade disease. 

It’s about Hormones

I believe that heterogeneity also extends to other areas producing even more shades of grey.  Let’s look at syndromes as one major example:


  • Non-functioning tumours—no specific clinical syndrome is observed
  • Functioning tumours—the tumours’ secretions lead to clinical symptoms

When you read the content of the average social media patient group, it’s almost as if everyone has a syndrome and often there is only one syndrome mentioned.  Statistics collected over decades are ignored and this issue is exacerbated by flawed statistics emanating from advocate organisations. But in reality, only 10% of cases involve carcinoid syndrome (where appropriate) and, in another example, 75-90% of pancreatic NETs are said to be non-functional

Most cases of functioning tumours are related to the late stages, but the earlier appearance of syndromes remains possible in some NETs, e.g. ovarian.  NETs of the foregut and lungs do not contain the enzyme aromatic L-amino acid decarboxylase which converts 5-hydroxytryptophan to serotonin, thus, they do not normally produce serotonin.  Most Gastric, Lung and Rectal NETs will not be functional but when they are, it could be a form of atypical carcinoid syndrome likely to be from other dominant hormones such as histamine rather than serotonin. And it could be a side effect of the tumour growth rather than a syndrome e.g. wheezing caused by an obstruction to the airways is not carcinoid syndrome wheezing.   Carcinoid syndrome is highly unusual in a pancreatic NET and doctors and patients should be looking for the known pancreatic syndromes in equal endeavour where a functional/symptomatic pancreatic NET is suspected. 

Hindgut NETs usually do not normally produce any bioactive hormone. They are normally unable to convert tryptophan to serotonin and other metabolites and therefore rarely cause carcinoid syndrome even if they metastasise to the liver.

Sorting out the symptoms

When you consider the above, it should not be a surprise to know that different types of NET will produce different symptoms.  These symptoms may be from two main sources; side effects of the tumour growth affecting local areas and if the tumour is functional, from the relevant syndrome producing the effect. AND YET when I read authoritative sites written by healthcare professionals, written by advocacy organisations, and also comments made in patient groups, you might end up thinking there is only one syndrome with two symptoms.  For example, flushing.  The inference on many sites is that this is caused by so-called carcinoid syndrome, but it is also a potential symptom of Pheochromocytoma/Paraganglioma, Medullary Thyroid Cancer and certain pancreatic NETs.  Many people claim this is due to elevated serotonin and yet even within carcinoid syndrome cases, it is most likely the case that serotonin is not even the dominant hormone involved.  Similarly, let’s look at diarrhea.  In many cases, this will be caused by a myriad of reasons, including some issues not even related to NETs.  Even within NETs, the suggestion that it is carcinoid syndrome is very often way off beam, as surgery and other therapies will be related to these issues in many cases. Serotonin is most likely the dominant hormone causing syndrome diarrhea.  BUT there are other types of NETs that are not serotonin-secreting that may have diarrhea as a side effect (not caused by carcinoid syndrome!). Examples include but are not limited to; Medullary Thyroid Cancer, Pheochromocytoma / Paraganglioma, and pancreatic NETs where the malabsorption symptoms of pancreatic exocrine insufficiency (PEI) are often confused with diarrhea.  The PEI issue may also affect any patient receiving long-term somatostatin analogues

It’s infrequently about Genetics

Only around 5-10% are related to genetic or hereditary diseases. Read more here:


Future editions of NEN classifications may include molecular profiling for each ‘shade of grey’ supplementing guidelines, not only helping with diagnosis but also providing a more individualised patient guidance on the right treatment and/or surveillance periods. The total number of shades of grey will undoubtedly increase. 

We have a duty to think before we make blanket statements about Neuroendocrine Neoplasms. The only real common feature is the cell type origin, nearly everything else is different. 

Click picture to read


I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me.  Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional as they are not members of the private group or followers of my sites in any official capacity.  Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

Subscribe to my newsletter

Thanks for reading.


I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


RonnyAllan.NET – Summary of January 2023 – Ronny Allan – Living with Neuroendocrine Cancer

Summary Great start to 2023 and I thank those who continue to support my social media and this blog.  I’m keen to hear any suggestions

Read More »

Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies (incl NET)

Trial Summary This interesting trial is a multi-cancer effort including NET.  The phase I clinical trial of Procaspase Activating Compound-1 (PAC-1), a drug that spurs

Read More »

Dustin Diamond

I’m behind the curve on this one after being ahead on celebrities such as Steve Jobs, Aretha Franklin, Wilko Johnson and Olivia Williams.  But in

Read More »

Neuroendocrine tumors are uncommon but definitely not rare

USA finally commits  UK and Australian figures recently confirmed that Neuroendocrine Cancer is the 10th and 7th most common cancer type.  It was great to

Read More »

Cancer Ablation

What is Cancer Ablation? This is a minimally invasive surgical method to treat solid cancers. Special probes are used to “burn” or “freeze” cancers. Computed

Read More »

Lactose intolerance – the NET Effect

Background   When I cast my mind back to my very first surgery, I remember asking my Oncologist what I could do to put on weight. 

Read More »

EUS Guided Ablation for small pancreatic NETs (Less than 2cm)

To burn or not to burn? I once wrote a post about Pancreatic NET “to cut or not to cut”.  You can read that here. 

Read More »

RonnyAllan.NET – a review of 2022

Review In 2022, my pet project (my blog) hit 2 million views in early November – that was a major boost.  It takes 3-4 years to get

Read More »

RonnyAllan.NET – Summary of December 2022

Summary December is always the quietest month of the year, no surprise why!  However, the top 10 below is somewhat surprising, I guess some posts

Read More »

One thought on “Neuroendocrine Cancer: At least 50 shades of grey

  • Gaynor miles

    Hi Ronny. Just read this again. I am always amazed by your knowledge of nets and the way you explain things.

I love comments - feel free!

%d bloggers like this: